Thanks to our partner, Mochi Health! https://JoinMochi.com

In this episode of Hims House, Jonathan Stern sits down with Sabina Hemmi (founder of GLP Winner), for the most comprehensive episode on GLP-1s that Hims House has done. They cover the compounding wars -- federal legislation, state-level crackdowns, and the lawsuits -- before diving into why tirzepatide dominates patient demand and what might be holding Hims back from offering it. The discussion spans oral GLP-1s, microdosing trends, and concludes with Sabina's skeptical take on peptides.

00:00 - Sponsor: Mochi Health

02:59 - Video games → GLP-1s

04:56 - GLP Winner Overview

10:28 - Who does Hims actually compete with?

16:43 - Hims x Novo Relationship

23:17 - Why tirzepatide is superior

29:30 - The SAFE Drugs Act

32:23 - State Bills: Indiana, Florida, Virginia

40:43 - Adverse events

43:09 - GLP-1 pill vs. injectables

50:57 - Over-the-Counter GLP-1 coming soon?

52:55 - Peptides

Not financial, legal, or medical advice

Subscribe to Hims House:

https://himshouse.com/subscribe

Follow Sabina:

Tiktok: https://www.tiktok.com/@lawliepop

Instagram: https://www.instagram.com/lawliepops

Youtube: https://www.youtube.com/@lawliepop

X/Twitter: https://x.com/lawliepop

Substack: https://substack.com/@lawliepop

Linkedin: https://www.linkedin.com/in/sabina-hemmi

Follow us:

https://x.com/himshouse

https://x.com/jonathanrstern

Join the Discord:

https://discord.gg/tJqGgVhkEt